

LABORATORIOS KARIZOO, S.A.
BALANCE SHEET AS AT 31ST MARCH 2022
 All amounts are in Euros

Particulars	Note No.	As at 31st Mar 2022	As at 31st Mar 2021
ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	3	7.099.353	7.337.014
(b) Capital work in progress	4	170.611	16.601
(c) Intangible Assets	5	938.087	868.921
(d) Financial Assets			
(i) Investments	6	237.550	239.002
(ii) Loans	7	518.818	816.913
(e) Deferred tax assets (net)	18	178.648	-
Total Non-current assets		9.143.067	9.278.452
2 Current assets			
(a) Inventories	8	7.745.723	6.409.602
(b) Financial Assets			
(i) Trade receivables	9	6.936.189	8.080.580
(ii) Cash and cash equivalents	10	498.966	596.372
(iii) Loans	11	332.712	572.050
(iv) Others	12	4.286	6.096
(c) Other current assets	13	198.567	129.784
		15.716.442	15.794.483
TOTAL ASSETS		24.859.509	25.072.936
EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital	14	356.742	356.742
(b) Other Equity	15	8.448.303	7.758.524
Total Equity		8.805.044	8.115.265
2 Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	16	2.177.462	1.873.098
(ii) Lease Liabilities	37	1.632.422	2.008.703
(iii) Other financial liabilities	17	569.522	458.311
(iv) Deferred tax Liability (net)	18	-	23.729
Total Non-Current Liabilities		4.379.407	4.363.841
3 Current liabilities			
(a) Financial Liabilities			
(i) Short-term borrowings	19	4.449.803	5.264.701
(ii) Trade payables	20	5.536.098	5.161.280
(iii) Lease Liabilities	37	336.916	347.412
(iv) Other financial liabilities	21	1.109.478	1.316.758
(b) Other current liabilities	22	190.278	329.373
(c) Current tax liabilities	23	52.485	174.306
Total Current liabilities		11.675.058	12.593.830
TOTAL EQUITY AND LIABILITIES		24.859.509	25.072.936

The accompanying notes are an integral part of the financial statements.

As per our report of event date

BOYE MONTERO Y ASOCIADOS

Auditors & Consultants

C/ Madrid 107
 08006 BARCELONA
 N.I.F. B-08.639.734

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS



KARIZOO

LABORATORIOS KARIZOO, S.A.
 NIF: A08166002

Eusebi Vila Viña **Ramon Vila Viña**
 Director Director

Place : Barcelona, Spain

Date :


ALDIO FERREIRA

LABORATORIOS KARIZOO, S.A.
PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2022
 All amounts are in Euros

Particulars	Note No	Year ended 31 Mar 2022	Year ended 31 Mar 2021
(I) Revenue From Operations	24	35.475.622	34.885.786
(II) Other Income	25	231.947	160.827
(III) Total Income (I+ II)		35.707.569	35.046.614
(IV) EXPENSES			
Cost of materials consumed	26	26.389.461	24.814.161
Changes in inventories of finished goods and work-in-progress & intermediates	27	(864.920)	(41.982)
Employee benefits expense	28	5.086.520	4.339.769
Finance costs	29	175.648	208.592
Depreciation and amortization expense	30	1.114.499	939.566
Other expenses	31	3.541.614	3.268.585
Total expenses (IV)		35.442.823	33.528.691
(V) Profit before tax (III- IV)		264.746	1.517.923
(VI) Tax expense:	32		
(1) Current tax		89.156	287.619
(2) Deferred tax		-202.550	13.007
(VII) Profit after tax		378.140	1.217.297
(VIII) Earnings per equity share:	33		
(1) Basic		38,22	123,05
(2) Diluted		38,22	123,05

The accompanying notes are an integral part of the financial statements.

As per our report of even date
BOVÉ MONTERO Y ASOCIADOS
 Auditors & Consultants



Place : Barcelona, Spain
 Date :

ILIDIO FELIPEIRA

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS



KARIZOO

LABORATORIOS KARIZOO, S.A.
 NIF: A068818502

Eusebi Vila Viña
Eusebi Vila Viña
 Director

Ramon Vila Viña
Ramon Vila Viña
 Director

LABORATORIOS KARIZOO, S.A.
Notes to the financial statements for the year ended 31 March, 2022
All amounts are in Euros

Note no

14 (a) Equity share capital

(i) Authorised Share Capital
9893 share of Euro 36.06 each
(ii) Issued Share Capital
9893 share of Euro 36.06 each

Notes :

(i) Reconciliation of the number of shares and amount outstanding at the beginning and end of the reporting period

As at 31st Mar 2022		As at 31st Mar 2021	
No. of Shares	Amount	No. of Shares	Amount
9893	356.742	9893	356.742
9.893	356.742	9.893	356.742
9.893	356.742	9.893	356.742

No. Equity shares

Add : Shares issued during the period
Shares outstanding at the end of the period

(ii) Terms / Rights attached to Equity Shares

In the Event of liquidation of the company, the shareholders of the equity shares will be entitled to receive the remaining assets of the company, after distribution of the all preferential amounts, if any. The distribution will be in the proportion to the number of equity shares held by the share holders

(iii) Details of Shares held by each share holder

Name of Share Holders
Vila Viña Participacions S.L.
Alivira Animal Health Limited, Ireland
Teresa Vila Viña
Eusebi Vila Viña
Ramón Vila Viña

As at 31st Mar 2022		As at 31st Mar 2021	
No. of Shares	% holding	No. of Shares	% holding
9.878	99,85%	9.878	99,85%
9	0,09%	9	0,09%
2	0,02%	2	0,02%
2	0,02%	2	0,02%
2	0,02%	2	0,02%

15 (b) Other Equity

Balance at the beginning of the reporting year
Add: Profit for the year
Less : Dividend paid
Share Options Outstanding Account
Balance at the end of the reporting year

As at 31st Mar 2022		As at 31st Mar 2021	
Retained Earnings	Total	Retained Earnings	Total
5.442.292	7.758.524	4.454.996	6.771.227
378.141	378.141	1.217.297	1.217.297
(65.000)	(65.000)	(230.000)	(230.000)
376.638	376.638	-	-
6.132.071	8.448.303	5.442.292	7.758.524

As at 31st Mar 2022		As at 31st Mar 2021	
Securities Premium reserve	General reserve	Securities premium reserve	General reserve
228.598	2.040.724	228.598	2.040.724
-	-	-	-
-	-	-	-
228.598	2.040.724	228.598	2.040.724
46.910	46.910	46.910	46.910
-	-	-	-
-	-	-	-
46.910	46.910	46.910	46.910
8.448.303	8.448.303	7.758.524	7.758.524



LABORATORIOS KARIZOO, S.A.
Statement of cash flows for the period ended 31 March, 2022
All amounts are in Euro

Particulars	Period ended 31 March, 2022	Period ended 31 March, 2021
Cash flow from Operating Activities :		
Profit/(Loss) before tax	264.746	1.517.923
Adjustments for:		
Add:- Interest	175.648	208.592
Add: Depreciation	1.114.499	939.566
Add: Employee stock option expense	376.638	
Operating profit before working capital changes	1.931.530	2.666.081
Change in working Capital		
Increase (-)/Decrease(+) in Current Asset		
Inventories	(1.336.121)	(8.977)
Trade receivables	1.144.391	(493.388)
Other current assets	(77.916)	15.291
Increase (+)/Decrease(-) in Current Liabilities		
Trade payables	374.353	(421.020)
Other financial liabilities		
Other current liabilities	(135.272)	401.825
Net change in working capital	(30.564)	(506.269)
Cash generated from operations	1.900.966	2.159.812
Direct taxes (paid)/refund	(210.977)	(309.719)
Net cash generated/(used in) from operating activities	1.689.990	1.850.094
Cash Flow from Investing activities		
Purchase of fixed assets	(1.100.108)	(646.049)
Dividend paid to Share holders	(65.000)	(230.000)
Net cash used in investing activities	(1.165.108)	(876.049)
Cash flow from Financing activities		
Borrowings during the period (Net)	(1.351.419)	(1.165.251)
Lease liability repay	(386.777)	(386.777)
(Loan given to)/ repaid by related parties	549.695	542.795
Loan given by/ (repaid) to related parties	741.426	-
Finance cost	(175.214)	(206.170)
Net cash used in investing activities	(622.288)	(1.215.402)
Net increase/(decrease) in cash and cash equivalents during the period	(97.406)	(241.357)
Opening Cash & cash equivalent at the beginning of the period	596.372	837.729
Cash and cash equivalents at the end of the period	498.965	596.372
Reconciliation of cash and cash equivalents with the Balance sheet		
Cash on hand	2.386	577
Balances with banks	496.580	595.795
Cash and cash equivalents as per Balance Sheet	498.966	596.372

The accompanying notes are an integral part of the financial statements.

As per our report of even date

BOVE MONTERO Y ASOCIADOS

Auditors & Consultants

Plaza de España, 7
 08002 BARCELONA
 N.I.F. B-08039734

Place, Barcelona Spain
 Date

ILIBOTERRERA



KARIZOO

LABORATORIOS.KARIZOO,S.A.
 NIF: A08818502

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Eusebi Vila Viña
Eusebi Vila Viña
 Director

Ramon Vila Viña
Ramon Vila Viña
 Director

Laboratorios Karizoo SA
Notes forming part of the financial statements

Note

1 Legal status and principal activities

Laboratorios Karizoo SA ("The Company") founded in 1983, dedicated to manufacture and distribute veterinary medical and nutritional products. The corporate office is located in Caldes de Montbui, Barcelona (Spain). Laboratorios Karizoo is committed to the veterinary sector and its main objective is to improve the health and well-being of farm animals as well as the health and quality of life of pets.

2 Significant accounting policies

2.1 Changes in accounting policies and disclosures:

New and amended standards

The Company applied Ind AS 116 Leases for the first time. The nature and effect of the changes as a result of adoption of this new accounting standard is described below.

Several other amendments apply for the first time for the year ending 31 March 2019, but do not have an impact on the consolidated financial statements of the Company. The Company has not early adopted any standards, amendments that have been issued but are not yet effective/notified.

Ind AS 116 Leases

Ind AS 116 supersedes Ind AS 17 Leases including its appendices (Appendix C of Ind AS 17 Determining whether an Arrangement contains a Lease, Appendix A of Ind AS 17 Operating Leases-Incentives and Appendix B of Ind AS 17 Evaluating the Substance of Transactions Involving the Legal Form of a Lease). The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet.

Lessor accounting under Ind AS 116 is substantially unchanged from Ind AS 17. Lessors will continue to classify leases as either operating or finance leases using similar principles as in Ind AS 17. Therefore, Ind AS 116 does not have an impact for leases where the Company is the lessor.

The Company adopted Ind AS 116 using the full retrospective method of adoption, with the date of initial application on 1 April 2019. The Company elected to use the transition practical expedient to not reassess whether a contract is, or contains, a lease at 1 April 2019. Instead, the Company applied the standard only to contracts that were previously identified as leases applying Ind AS 17 and Appendix C of Ind AS 17 at the date of initial application. The Company also elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option (short-term leases), and lease contracts for which the underlying asset is of low value (low-value assets).

2.2 Basis of accounting and preparation of financial statements

The Financial Statements have been prepared on accrual basis under the historical cost convention except for certain categories of fixed assets that are carried at revalued amounts.

The financial statements of Laboratorios Karizoo SA ('the Company') have been prepared, in accordance with with Spanish accounting standards. The Financial Statements have been prepared on accrual basis.

Effective 1 June 2016, Alivira Animal Health Limited, Ireland (step down subsidiary of Sequent Scientific Limited) acquired stake of 60% in Vila Vina Participacions SL which is the holding company of Laboratorios Karizoo SA.

The financial statements are prepared for the period 1 April 2021 to 31 March 2022 for the purpose of consolidation with its ultimate holding Company 'Sequent Scientific Limited'



Laboratorios Karizoo SA
Notes forming part of the financial statements

2,3 Tangible fixed assets

Fixed assets are carried at cost less accumulated depreciation and impairment losses, if any. The cost of fixed assets comprise its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than the subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets to the date the asset is ready for its intended use. Exchange differences arising on restatement/ settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

2,4 Intangible fixed assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

An intangible asset is derecognised upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

2,5 Depreciation

Depreciation is provided under the straight-line method based on the useful lives:

Nature of Asset	Useful life in periods (range)
Buildings	10 - 75
Plant and Machinery	2 -25
Technical Facilities	10 - 30
Technical Installations	2 - 15
Office Equipment	3 - 10
Vehicles	2 - 8
Furniture and Fixtures	5 - 15



Laboratorios Karizoo SA
Notes forming part of the financial statements

2,6 Impairment of assets

The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment if any indication of impairment exists. The following intangible assets are tested for impairment each financial period even if there is no indication that the asset is impaired:

(a) an intangible asset that is not yet available for use; and (b) an intangible asset that is amortised over a period exceeding ten periods from the date when the asset is available for use.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognised for such excess amount. The impairment loss is recognised as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognised for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognised.

2,7 Inventory

Inventories comprises of raw materials and finished goods. These are valued at the lower of cost and net realizable value. Cost is determined on First in First out basis.

(i) Raw materials & packing material :

At purchase cost including other cost incurred in bringing materials to their present location and condition

(ii) Work in process, intermediates & Finished goods :

At material cost, conversion cost and appropriate share of production overheads

2,8 Revenue recognition

The Group presents revenue net of indirect taxes in its Statement of Profit and Loss.

Sale of goods

Revenue from sale of products is presented in the income statement within Revenue from operations. The Group presents revenue net of indirect taxes in its statement of profit and loss. Sale of products comprise revenue from sales of products, net of sales returns, and of customer discounts.

Revenue is recognised when it is probable that future economic benefits will flow to the Company and these benefits can be measured reliably. Further, revenue recognition requires that all significant risks and rewards of ownership of the goods included in the transaction have been transferred to the buyer, and that Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold. Performance obligations are satisfied at one point in time, typically on delivery. Revenue is recognized when the Company transfers control over the product to the customers; control of a product refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, that asset. The majority of revenue earned by the Company is derived from the satisfaction of a single performance obligation for each contract which is the sale of products.

Sales are measured at the fair value of consideration received or receivable. The amounts of rebates/incentives is estimated and accrued on each of the underlying sales transactions recognised. Returns and customer discounts are recognized in the period in which the underlying sales are recognized. The amount of sales returns is calculated on the basis of management's best estimate of the amount of product that will ultimately be returned by customers.



Laboratorios Karizoo SA
Notes forming part of the financial statements

Services

Income from technical service, support services and other management fees is recognised when the services are completed as per the terms of the agreement and when no significant uncertainty as to its determination or realisation exists.

Income from analytical service is recognised when the services are completed as per the terms of the agreement and when no significant uncertainty as to its determination or realisation exists. Revenue is recognised net of taxes and discounts.

Export entitlements

Export entitlements from Government authorities are recognised in the statement of profit and loss when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Group, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Interest and dividend income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable.

Dividend income from investments is recognised when the right to receive payment has been established.

2,9 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

There are no carry forward of leave balances.

2,10 Foreign currency transactions

Initial recognition

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Foreign currency monetary items of the Company outstanding at the Balance Sheet date are restated at the period-end rates. Non monetary items of the Company are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the period.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of foreign currency monetary assets and liabilities of the Company are recognised as income or expense in the statement of profit and loss.

2,11 Taxes on income

Income Tax comprises the current tax provision. Current tax is the amount of tax payable on the taxable income for the period.

2,12 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.



A handwritten signature in blue ink, consisting of a large, stylized initial 'P' followed by a smaller, less distinct signature.

Laboratorios Karizoo SA
Notes forming part of the financial statements

2,13 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

2,14 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management believes that the estimates used in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2,15 Segment

Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the internal reporting system.

2,16 Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that there is no uncertainty in receiving the claims.

2,17 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

2,18 Leases

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including insubstance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

The Company's lease liabilities are included in Interest-bearing loans and borrowings (see Note 37).



A handwritten signature in blue ink, consisting of a large, stylized initial 'B' followed by a smaller, less distinct signature.

Laboratorios Karizoo SA

Notes forming part of the financial statements

2,19 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.

2,20 Cash and cash equivalents (for purposes of cash flow statement)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2,21 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.



A handwritten signature in blue ink, consisting of several overlapping loops and a final flourish.

LABORATORIOS KARIZOO, S.A.
Notes to the financial statements for the year ended 31 March, 2022
All amounts are in Euros

Note 3 : Property, plant and equipment

Particulars	As at 31 March, 2022	As at 31 March, 2021
Carrying Amount of:		
Freehold land	176.014	176.014
Buildings	940.773	979.700
Furniture and fixtures	131.501	141.697
Computers	25.217	72.628
Plant and machinery	3.689.276	3.510.426
Vehicles	169.367	204.613
Right to use Assets	1.854.032	2.251.854
Total	6.986.181	7.336.931

Note 4 : Capital Work in progress

Particulars	As at 31 March, 2022	As at 31 March, 2021
Carrying Amount of:		
Capital Work in Progress	170.610	16.601
Total of PPE and CWIP	7.156.791	7.353.533

Particulars	Freehold land	Buildings	Furniture and fixtures	Computers	Plant and machinery	Vehicles	Right to use Assets	Capital Work in Progress	Total
Cost or deemed cost									
Balance as on 01 April, 2020	176.014	1.136.428	172.519	114.586	4.485.612	294.797	3.014.269	200.540	9.594.765
Assets acquired	-	-	2.721	14.288	100.925	91.590	29.232	264.609	503.364
Deletions	-	-	(600)	(10.143)	(48.132)	(68.956)	-	(448.547)	(576.378)
Balance as on 01 April, 2021	176.014	1.136.428	174.640	118.731	4.538.405	317.431	3.043.500	16.601	9.521.751
Assets acquired	-	4.816	3.761	6.291	742.186	28.819	-	154.009	939.882
Deletions	-	-	-	-	(110.584)	(3.719)	-	-	(114.303)
Balance as on 31 March, 2022	176.014	1.141.245	178.401	125.022	5.170.007	342.531	3.043.500	170.610	10.347.330

Particulars	Freehold land	Buildings	Furniture and fixtures	Computers	Plant and machinery	Vehicles	Right to use Assets	Capital Work in Progress	Total
Accumulated depreciation and impairment									
Balance as on 01 April, 2019	-	113.050	21.208	23.009	747.600	96.678	394.018	-	1.395.564
Depreciation / amortisation expense for the year	-	43.678	12.335	33.237	326.180	60.616	397.629	-	873.674
Accumulated dep for assets sold	-	-	600	10.143	(44.475)	(44.475)	-	-	12.068
Balance as on 01 April, 2021	-	156.728	34.143	66.388	1.119.581	112.818	791.647	-	2.281.306
Depreciation / amortisation expense for the year	-	43.744	12.758	33.417	361.150	60.345	397.821	-	909.235
Accumulated dep for assets sold	-	-	-	-	-	-	-	-	-
Balance as on 31 March, 2022	-	200.472	46.900	99.806	1.480.731	173.163	1.189.468	-	3.190.540

Particulars	Freehold land	Buildings	Furniture and fixtures	Computers	Plant and machinery	Vehicles	Right to use Assets	Capital Work in Progress	Total
Carrying amount									
Balance as on 01 April, 2021	176.014	979.700	140.498	52.343	3.418.824	204.613	2.251.854	16.601	7.240.446
Balance as on 31 March, 2022	176.014	940.773	131.501	25.217	3.689.276	169.367	1.854.032	170.610	7.156.790



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

Note 5: Intangible Assets

Particulars	As at 31 March, 2022	As at 31 March, 2021
Carrying Amount of:		
Software License Fees	378.679	453.396
Registration fees	555.942	415.524
Total	934.621	868.919

Particulars	Software Lisc Fees	Registration fees	Total
Cost or deemed cost			
Balance as on 01 April, 2020	23.052	322.453	345.505
Assets acquired	453.461	209.176	662.638
Deletions	(1.733)	-	(1.733)
Balance as on 01 April, 2021	474.780	531.629	1.006.409
Assets acquired	1.428	273.101	274.529
Deletions	-	-	-
Balance as on 31 March, 2022	476.208	804.730	1.280.938

Particulars	Software Lisc Fees	Registration fees	Total
Accumulated depreciation and impairment			
Balance as on 01 April, 2020	5.934	67.397	73.331
Depreciation / amortisation expense for the year	17.184	48.709	65.892
Accumulated dep for assets sold	1.733	-	1.733
Balance as on 01 April, 2021	24.850	116.106	140.956
Depreciation / amortisation expense for the year	72.679	132.682	205.361
Accumulated dep for assets sold	-	-	-
Balance as on 31 March, 2022	97.529	248.788	346.317

Particulars	Software Lisc Fees	Registration fees	Total
Carrying amount			
Balance as on 01 April, 2021	453.396	415.524	868.919
Balance as on 31 March, 2022	378.679	555.942	934.621



Note no	Particulars	As at 31st Mar 2022 (Amount in Euro)	As at 31st Mar 2021 (Amount in Euro)					
	Financial assets							
6	Non-current Investments							
	Investments in equity instruments - Subsidiaries	236,837	236,837					
	Investments in equity instruments - Others	713	2,165					
		237,550	239,002					
7	Other Non-Current Financial assets							
	Security Deposits	56,177	51,945					
	Loans to Related Parties	462,640	764,969					
		518,818	816,913					
11	Deferred tax assets (net)							
	Deferred tax liabilities							
	- Temporary differences on account of depreciation	68,317	49,794					
	Total deferred tax liabilities (A)	68,317	49,794					
	- Temporary differences on account of depreciation	5,261						
	- Temporary differences on account of right-of-use assets	28,827	26,065					
	Others	212,877	-					
	Total deferred tax assets (B)	246,965	26,065					
	Total (B) - (A)	178,648	(23,729)					
8	Inventories							
	(At lower of cost and net realisable value)							
	Raw materials and packing materials	3,542,477	3,071,276					
	Work-in-progress and intermediates	273,936	237,416					
	Finished goods	1,526,181	1,051,099					
	Stock in Trade	2,403,128	2,049,811					
		3,929,310	3,100,910					
		7,745,723	6,409,602					
	Note: During the year ended March 2022 19,478 (March 2021 8,663) was recognized as expense towards slow moving, expired and near expiry inventories							
9	Financial Assets							
	Trade receivables							
	Aggregate amount of Trade and Other							
	(a) Unsecured, considered good	6,936,189	8,080,580					
	(b) Unsecured, considered doubtful	94,699	97,199					
		7,030,887	8,177,779					
	Less: Provision for doubtful debts	(94,699)	(97,199)					
		6,936,189	8,080,580					
	Note : Overdue for more than 180 days as on March 21 Eur 157,433							
	<u>Ageing as at 31.03.2022</u>							
		Outstanding for following periods from						
	Particulars	Not Due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	Total
	(i) Undisputed Trade Receivables - considered good	6,296,672	639,517	-	-	-	-	6,936,189
	(ii) Undisputed Trade Receivables - considered doubtful	-	-	-	-	-	94,699	94,699
	<u>Ageing as at 31.03.2021</u>							
		Outstanding for following periods from						
	Particulars	Not Due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	Total
	(i) Undisputed Trade Receivables -	7,139,729	789,113	150,875	863	20	-	8,080,600
	(ii) Undisputed Trade Receivables -	-	-	-	-	3,510	93,669	97,179
10	Cash and cash equivalents							
	Cash on hand	2,386						577
	Balances with banks							
	- In current accounts	496,580						595,471
	In earmarked accounts							
	- Margin money deposits	-						324
		498,966						596,372
11	Current Loans							
	Unsecured, considered good;							
	Advances to employees	10,385						2,356
	Loans & Advances to related parties	322,328						569,694
		332,712						572,050
12	Other current financial assets							
	Interest on Related Party Loans	4,286						6,096
		4,286						6,096
13	Other current assets							
	Balances with government authorities	40,460						53,835
	Prepaid expenses	101,331						72,396
	Others	1,214						3,553
		198,567						129,784



[Handwritten signature and scribbles]

LABORATORIOS KARIZOO, S.A.
Notes to the financial statements for the year ended 31 March, 2022
All amounts are in Euros

Note no	Particulars	As at 31st Mar 2022	As at 31st Mar 2021					
16	Other Non-current Financial liabilities							
	From banks							
	Secured	80.560	95.368					
	Unsecured	1.281.465	1.637.479					
	From Related parties	741.426	-					
	From other parties							
	Secured	74.012	101.172					
	Unsecured	-	39.080					
		2.177.462	1.873.098					
17	Other Non-current financial liabilities							
	Finance lease obligation	569.522	458.311					
		569.522	458.311					
19	Current Financial Liabilities - Short term borrowings							
	(a) Loans repayable on demand							
	From banks							
	Unsecured	4.262.075	3.256.095					
	Bills Discounted	187.728	2.008.606					
		4.449.803	5.264.701					
20	Trade payable							
	Trade payable	5.536.098	5.161.280					
		5.536.098	5.161.280					
Ageing as at 31.03.2022								
Particulars		Outstanding for following periods from						
		Unbilled	Not Due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	Total
(i)	Undisputed Trade Payables	239.637	5.111.622	128.837	442	-	-	5.480.537
Ageing as at 31.03.2021								
Particulars		Outstanding for following periods from						
		Unbilled	Not Due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	Total
(i)	Undisputed Trade Payables	64.462	5.035.227	61.591	-	-	-	5.161.280
21	Other Current Financial liabilities							
	Current maturities of long-term debt	777.442						1.092.183
	Interest accrued and due on borrowings	1.989						2.422
	Finance lease payables	322.898						218.826
	Other current liabilities	7.150						3.326
		1.109.478						1.316.758
22	Other Current Liabilities							
	Other payables							
	(i) Statutory remittances	165.978						305.073
	(ii) Advances from customers	24.300						24.300
		190.278						329.373
23	Current tax liabilities (Net)							
	Provision for taxation (Net off advance tax as at 31 March 2022 Euro 47,145.70 ; Mar 2021 Euro 341,454)	52.485						174.306
		52.485						174.306



Note 16 (i) Details of terms of repayment for the long-term borrowings and security provided in respect of the secured long-term borrowings:

Particulars	Security	Terms of repayment	As at 31st Mar 2022	As at 31st Mar 2021
Secured term loans from banks:				
Banc Sabadell	First Pari-passu charge on fixed assets of the Company's K4 building	Repayable in 180 monthly Instalments, commencing from March 2013. Repayable fully by February 2028	22.898	27.102
Banc Sabadell	First Pari-passu charge on fixed assets of the Company's K4 building	Repayable in 180 monthly Instalments, commencing from March 2013. Repayable fully by February 2028	57.662	68.265
Total			80.560	95.368

Particulars	Security	Terms of repayment	As at 31st Mar 2022	As at 31st Mar 2021
Unsecured term loans from banks:				
B.B.V.A.	Not Security	Repayable in 60 monthly Instalments, commencing from August 2020. Repaid fully on July 2025. Fixed Interest. First year grace period.	217.987	209.606
B.B.V.A.	Unsecured	Repayable in 60 monthly Instalments, commencing from May 2018. Repayable fully by April 2023.	1.188	15.371
Bank Popular	Unsecured	Repayable in 60 monthly Instalments, commencing from December 2018. Repayable fully by November 2023.	20.392	50.751
B.S.C.H.	Unsecured	Repayable in 60 monthly Instalments, commencing from December 2018. Repayable fully by November 2023.	20.392	50.751
Bankia	Unsecured	Repayable in 60 monthly Instalments, commencing from June 2019. Repayable fully by May 2024.	149.463	275.170
B.S.C.H.	Unsecured	Repayable in 20 quarterly Instalments, commencing from October 2019. Repayable fully by July 2024.	231.320	382.484
B.S.C.H.	Unsecured	Repayable in 20 quarterly Instalments, commencing from October 2019. Repayable fully by July 2024.	231.320	382.484
Banc Sabadell	Unsecured	Repayable in 60 monthly Instalments, commencing from December 2019. Repayable fully by November 2024.	170.428	270.861
ABANCA	Unsecured	Repayable in 60 monthly Instalments, commencing from May 2021. Repaid fully on May 2026. Fixed Interest. First year grace period.	238.975	-
Total			1.281.465	1.637.479

Particulars	Security	Terms of repayment	As at 31st Mar 2022	As at 31st Mar 2021
secured Term loans from other parties				
BMW Finance	Unsecured	Repayable in 48 monthly Instalments, commencing from November 2019. Repayable fully by October 2023.	6.029	15.830
Volkswagen Bank	Unsecured	Repayable in 36 monthly Instalments, commencing from August 2020. Repaid fully on July 2023. Fixed Interest	2.731	10.476
BMW Finance	Unsecured	Repayable in 48 monthly Instalments, commencing from July 2019. Repayable fully by June 2023.	23.786	25.185
Volkswagen Bank	Unsecured	Repayable in 48 monthly Instalments, commencing from October 2019. Repayable fully by September 2024.	41.465	49.681
Unsecured Term loans from other parties				
Dell Bank International	Unsecured	Repayable in 36 monthly Instalments, commencing from July 2019. Repayable fully by June 2022.	-	17.091
ICF	Unsecured	Repayable in 28 quarterly Instalments, commencing from Oct 2015. Repayable fully by July 2022.	-	21.990
Total			74.012	140.252
Grand Total			1.436.036	1.873.098

The interest on above loans are in ranges from 0.9% to 8.5% per annum



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

(ii) Details of Current Maturities of Long term borrowings

Particulars	As at 31st Mar 2022	As at 31st Mar 2021
<u>From Banks</u>		
<u>Secured</u>		
Bank Sabadell	4.205	4.067
Bank Sabadell	10.593	10.212
Total	14.798	14.280
<u>From Banks</u>		
<u>Unsecured</u>		
B.B.V.A.	32.013	40.394
Bankia		254.736
B.B.V.A.	14.183	14.042
La Caixa		11.267
Bank Popular	30.360	30.088
B.S.C.H.	30.360	30.088
Bankinter		42.357
Bankia	125.707	123.528
PRESTEC B.S.C.H.	151.164	148.769
PRESTEC B.S.C.H.	151.164	148.769
Banc Sabadell	100.433	99.087
ABANCA	61.025	-
	696.408	943.123
<u>From Other Parties</u>		
<u>Secured</u>		
BMW Finance	9.801	9.163
BMW Finance	1.398	1.317
Volkswagen Bank	8.216	7.587
Volkswagen Bank	7.745	7.116
<u>From Other Parties</u>		
<u>Unsecured</u>		
Dell Bank International	17.091	66.463
ICF	21.986	43.134
Total	66.237	134.780
Grand Total	777.442	1.092.183

(iii) Details of Short term borrowings

Particulars	As at 31st Mar 2022	As at 31st Mar 2021
<u>From banks:</u>		
<u>Unsecured</u>		
B.B.V.A.	308.104	120.774
Bankinter	428.333	731.474
B.S.C.H.	281.338	243.100
Bank Sabadell	1.483.279	1.376.814
La Caixa	1.304.412	220.860
Bankia	-	326.496
Banca March	56.569	151.703
ABANCA	400.041	84.874
	4.262.075	3.256.095

The interest on above loans are in ranges from 0.35% to 8.5% per annum.



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

Note no	Particulars	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Note 24	Revenue from operations		
	a) Sale of products	34.647.278	34.575.063
	b) Sale of services	350.415	131.718
	c) Other operating revenues	477.929	179.005
		35.475.622	34.885.786
	Reconciliation of revenue from sale of products and services with the contracted price:		
	Contracted Price	35.783.165	35.444.480
	Less : Sales discount and return	785.472	737.699
	Sales of product and services	34.997.693	34.706.782
Note 25	Other Income		
	Interest income	20.538	31.679
	Net gain on sale of investments	874	-
	Dividend Income	-	72
	Other non-operating income	9.183	16.047
	Net gain on foreign currency transactions and translation	201.352	113.029
		231.947	160.827
Note 26	Cost of materials consumed		
	Opening stock	3.071.276	3.104.281
	Add: Purchases	26.860.662	24.781.156
	Less: Closing stock	3.542.477	3.071.276
		26.389.461	24.814.161
Note 27	Changes in inventories of finished goods and work-in-progress & intermediates		
	Opening stock		
	Work-in-progress and intermediates	237.416	155.283
	Finished goods	1.051.099	1.043.304
	Stock in trade	2.049.811	2.097.757
		3.338.326	3.296.344
	Closing stock		
	Work-in-progress and intermediates	273.936	237.416
	Finished goods	1.526.181	1.051.099
	Stock in trade	2.403.128	2.049.811
		4.203.246	3.338.326
	Net (increase) / decrease	(864.920)	(41.982)
Note 28	Employee benefits expense		
	Salaries and wages	3.722.915	3.388.447
	Contribution to provident and other funds	936.803	879.720
	Expense on employee stock based compensation	376.638	-
	Staff welfare expenses	50.164	71.602
		5.086.520	4.339.769



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2020

All amounts are in Euros

Note no	Particulars	Year ended 31 Mar 2022 (Amount in Euro)	Year ended 31 Mar 2021 (Amount in Euro)
Note 29	Finance costs		
	Interest expense	116.939	135.320
	Other borrowing costs	20.321	34.883
	Lease Interest expense	38.389	38.389
		175.648	208.592
Note 30	Depreciation and amortization expense		
	Tangible assets	511.413	476.045
	Intangible assets	205.361	65.892
	Lease Amortisation (IND AS 116)	397.725	397.629
		1.114.499	939.566
Note 31	Other expenses		
	Travel expenses	85.567	36.156
	Communication expenses	45.782	52.148
	Contract labour charges	-	10.369
	Legal and Professional charges	929.649	845.118
	Freight and forwarding	575.680	637.661
	Power and fuel	275.801	224.672
	Rent expenses	80.054	50.972
	Analytical charges	51.317	64.942
	Repairs to machinery	256.368	316.285
	Repairs to others	240.051	144.349
	Insurance	153.067	126.513
	Marketing Expenses	324.106	218.469
	Rates and taxes	209.444	178.141
	Loss on sale of assets (net)	-	41.211
	Bad trade receivables written off	3.103	846
	Net loss on foreign currency transactions and translation	133.589	144.478
	Other expenses	178.037	176.254
		3.541.614	3.268.585
Note 32	Tax expense		
	Current tax	89.156	287.619
	Deferred tax	(202.550)	13.007
		(113.395)	300.626



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

Note

33 Earning per Share

Particulars	01 Apr 2021 to 31 March, 2022	01 Apr 2020 to 31 March, 2021
Net profit / (loss) for the period as per statement of profit and loss	378.140	1.217.297
Net profit / (loss) for the period attributable to the equity shareholders	378.140	1.217.297
Weighted average number of equity shares	9.893	9.893
Earnings / (Loss) per share - Basic	38,22	123,05
Earnings / (Loss) per share - Diluted	38,22	123,05

34 Segment Information

Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the internal reporting system.

Primary Segment : Business Segment

The Company through its subsidiaries is primarily engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. Considering the nature of the business and the financial reporting of the company, the company has only one business segment as the primary reportable segment.

I Revenue From Operations

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Asia	1.783.561	1.741.532
Europe	32.579.083	32.884.615
Rest of the World	1.112.978	259.639
Grand Total	35.475.622	34.885.786

II Total Assets

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Asia	470.272	186.670
Europe	24.121.745	24.805.361
Rest of the World	267.493	80.904
Total Segment Assets	24.859.509	25.072.935

III Cost incurred during the Year to acquire Segment Assets

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Europe	1.214.411	276.862
Rest of the World	-	75.000
Total	1.214.411	351.862

35 Contingent liabilities and commitments

(i) Contingent Liabilities

The company has received a resolution imposing a 30% benefit surcharge for an accident involving an employee dated 25/01/2021. The final cost to the company is subject to determination by the National Institute of Social Security

	As at 31st Mar 2022	As at 31st Mar 2021
	10.000	-

(ii) Capital Commitments

Tangible fixed assets
Intangible fixed assets
Total

	As at 31st Mar 2022	As at 31st Mar 2021
Tangible fixed assets	215.881	193.932
Intangible fixed assets	-	159.564
Total	215.881	353.496

36 Foreign currency exposure

Foreign currency (USD)	As at 31 Mar 2022	As at 31 Mar 2021
Trade Payable	699.772	1.122.827
Net Exposure	699.772	1.122.827



[Handwritten signature]

37 Details of leasing arrangements

The Company's significant leasing arrangement is mainly in respect of Vehicle.

The following is the movement in lease liabilities during the year ended 31 March 2022:

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Balance as at 1 April 2021	2.356.115	2.713.660
Addition during the year	-	29.232
Accretion of interest	38.389	38.389
Payments	(425.165)	(425.165)
Balance as at 31 March 2022	1.969.338	2.356.115
Current	336.916	347.412
Non-current	1.632.422	2.008.703

The effective interest rate for lease liabilities is 1.5%

The following are the amounts recognised in profit or loss:

	As at 31st Mar 2022	As at 31st Mar 2021
Depreciation expense of right-of-use assets	397.725	397.629
Interest expense on lease liabilities	38.389	38.389
Total amount recognised in profit or loss	436.114	436.017



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

38 Reconciliations of tax expenses and details of deferred tax balances

A) Income tax expense recognised in the statement of profit and loss

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
i) Income tax expense recognised in the statement of profit and loss		
Current tax	89.156	287.619
Total (I)	89.156	287.619
Deferred tax charge		
Origination and reversal of temporary differences	(202.550)	13.007
Total (II)	-202.550	13.007
Provision for tax of earlier years written back (III)	-	-
Total (IV = I+II+III)	-113.395	300.626

The current tax is calculated using tax rates that have been enacted or substantively enacted by the end of each reporting period.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the end of each reporting period.

B) Reconciliation of effective tax rate

The reconciliation between the statutory income tax rate applicable to the Company and the effective income tax rate of the Group is as follows:

	Year ended 31 Mar 2022	Year ended 31 Mar 2021
Profit before tax	264.746	1.517.923
Statutory income tax rate	25,00%	25,00%
Tax as per applicable tax rate	66.186	379.481
Differences due to:		
- Exempted income	-	61.352
- Others	179.581	17.503
Income tax expenses charged to the statement of profit and loss	(113.395)	300.626
Effective tax rate	-42,83%	19,81%

C) Movement in deferred tax assets and liabilities

	31 March 2022		
	As at 01 April 2021	Credit / (charge) in the statement of profit and loss	As at 31 March 2022
- Temporary differences on account of depreciation	(49.794)	(18.523)	(68.317)
- Right-of-use assets	26.065	2.761	28.827
- Other	-	218.138	218.138
Tax assets / (liabilities)	(23.729)	202.376	178.648

	31 March 2021		
	As at 01 April 2020	Credit / (charge) in the statement of profit and loss	As at 31 March 2021
- Temporary differences on account of depreciation	(34.272)	(15.522)	(49.794)
- Right-of-use assets	23.352	2.713	26.065
Total	-10.920	-12.809	-23.729

(^*) Opening balances is on account of transition impact of Ind AS 116.



39 Financial instruments

The carrying value / fair value of financial instruments by categories are as follows:

A)	Carrying value and fair value	
	31 March 2022	31 March 2021
Financial assets		
Measured at amortised cost		
Loans	851.530	1.388.963
Trade receivables	6.936.189	8.080.580
Cash and cash equivalents	498.966	596.372
Other bank balances		
Other financial assets	4.286	6.096
Other investments	237.550	239.002
Total	8.528.521	10.311.013
Financial liabilities		
Measured at amortised cost		
Borrowings (including current maturity of long-term borrowings)	7.216.979	6.221.376
Trade payables	5.536.098	5.161.280
Other financial liabilities	3.058.624	5.047.607
Total	15.811.701	16.430.263

The company's principal financial liabilities comprise loans and borrowings, trade payables and other payables. The main purpose of these financial liabilities is to finance the company's operations. The company's principal financial assets include investments, loans, trade and other receivables, and cash and deposits that derive directly from its operations.

The company is exposed to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

B) Liquidity risk

Liquidity risk is the risk that the company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The company approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company reputation.

The company has an appropriate liquidity risk management framework for the management of short, medium and long term funding and liquidity management requirements. The company manages liquidity risk by maintaining adequate cash reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2022 and 31 March 2021:

Particulars	As at 31 March 2022			
	Less than 1 year	1-2 years	2 years and above	Total
Borrowings (including current maturity of long-term borrowings and judicial recovery)	5.039.517	791.187	1.386.275	7.216.979
Trade payables	5.536.098	-	-	5.536.098
Lease Liability	336.916	313.988	1.318.434	1.969.338
Other financial liabilities	519.763	273.238	296.284	1.089.286

Particulars	As at 31 March 2021			
	Less than 1 year	1-2 years	2 years and above	Total
Borrowings (including current maturity of long-term borrowings and judicial recovery)	4.348.277	745.924	1.127.276	6.221.477
Trade payables	5.161.280	-	-	5.161.280
Lease Liability	347.412	336.916	1.671.787	2.356.115
Other financial liabilities	2.233.181	218.038	240.273	2.691.492

C) Interest rate risk exposure

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. At the reporting date the interest rate profile of the company's interest-bearing financial instruments are as follows:

	31 March 2021	31 March 2020
Financial liabilities		
-Borrowings from bank	6.239.947	5.836.697
-Borrowings from others	140.248	275.032
	6.380.196	6.111.728
Variable-rate instruments		
Financial liabilities		
-Borrowings from bank	95.358	109.647
Total	95.358	109.647

Fair value sensitivity analysis for fixed-rate instruments

The company does not account for any fixed rate financial assets and liabilities at fair value through profit or loss. Therefore a change in interest rates at the reporting date would not affect profit or loss.

Interest rate sensitivity analysis for variable-rate instruments

A change of 100 basis points in interest rates at the reporting date would have increased / (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant.

Effect

	Profit or loss	
	100 bps (increase)	100 bps decrease
31 March 2021		
Variable-rate instruments	(954)	954
	(954)	954
31 March 2020		
Variable-rate instruments	(1.096)	1.096
	(1.096)	1.096



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

D) Capital management

For the purpose of company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity share holders of the company. The primary objective of the company's capital management is to maximise the shareholder value.

The company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The company includes within net debt, interest bearing loans and borrowings less cash and cash equivalents

In order to achieve this overall objective, the company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would

	<u>31 March 2022</u>	<u>31 March 2021</u>
Debt (i)	7.216.979	6.221.376
Cash and bank balances (ii)	498.966	596.372
Other bank balances (iii) (margin money)	-	-
Other non-current financial assets (margin money) (iv)	-	-
Current investment (iv)	-	-
Net debt [(i) - { (ii)+(iii)+(iv) }]	<u>6.718.013</u>	<u>5.625.004</u>
Equity attributable to owners of the Company	8.805.044	8.115.265
Gearing ratio	<u>76,30%</u>	<u>69,31%</u>

(i) Debt is defined as long-term (including current maturity on long-term borrowings), short-term borrowings and judicial recovery.

(ii) Other bank balance exclude the bank balance towards unpaid dividend.

(iii) Gearing ratio : Net debt / Equity.



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

40 Related Party Disclosures:**A List of related parties:****i) Holding company:**

Vila Viña Participacions S.L.

Alivira Animal Health Limited, Ireland (Holding company of Vila Viña Participacions S.L.)

Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)

Sequent Scientific Limited, India (Ultimate Holding Company)

ii) Fellow Subsidiary :

Laboratorios Karizoo S.A. De C.V.

Phytotherapic Solutions S.L.

Comercial Vila Veterinaria De Lleida S.L

iii) Key Management Personnel

Ramon Vila Viña

Teresa Vila Viña

Eusebi Vila Viña

iv) Other Group Subsidiaries :

Alivira Italia S.R.L

Bremer Pharma GmbH

Fendigo SA

Fendigo BV

N-Vet AB

Provet Veterinerlik Urunleri Tic. Ltd. Sti

Tomkim Ilac Premiks San. ve Tic. A.S

Alivira (France)

Alivira UA Limited

Alivira Animal Health UK Ltd

Alivira Saude Animal Brasil Participacoes Ltda


Evanvet Distribuidora De Produtos Veterinarios Ltda (Name changed from 'Evance Saude Animal Ltda)

Alivira Saude Animal Ltda. (Name changed from Interchange Veterinária Indústria E Comércio Ltda)

Nourri Sac nutria Animal (Nourrie)

B. Transaction during the period

Nature of transactions	Year ended 31 Mar 2022	Year ended 31 Mar 2021
(i) Sales		
Comercial Vila Veterinaria De Lleida S.L	3.336.493	3.293.352
Phytotherapic Solutions S.L.	192.160	152.386
Fendigo SA	374.023	474.779
Alivira Animal Health Limited, Ireland	386.876	157.920
Alivira Animal Health Limited, Italy	-	191.317
N-Vet AB	-	14.000
Bremer Pharma GmbH	9.504	
Tomkim Ilac Premiks San. ve Tic. A.S	111.840	9.356
Alivira Animal Health Limited, India	3.192	-




LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022

All amounts are in Euros

Nature of transactions	Year ended 31 Mar 2022	Year ended 31 Mar 2021
(ii) Purchases		
Bremer Pharma Gmbh	1.868	-
Alivira Animal Health Limited, India	420	-
Fendigo SA	7.500	-
Alivira (France)	3.752	-
Alivira Animal Health Limited, Ireland	619.700	251.453
Phytotherapeutic Solutions S.L.	363.074	-
Comercial Vila Veterinaria De Lleida S.L	24.558	-
(iii) Analytical charges (income)		
Phytotherapeutic Solutions S.L.	15.782	17.918
(iv) Job Work Charges (income)		
Phytotherapeutic Solutions S.L.	120.613	96.755
(v) Marketing expense Received		
Phytotherapeutic Solutions S.L.	12.000	12.000
(vi) Interest Recd		
Alivira Animal Health Limited, Ireland	19.538	30.486
Laboratorios Karizoo S.A. De C.V.	1.000	1.000
(vii) Rent Recd		
Phytotherapeutic Solutions S.L.	5.049	4.950
Vila Viña Participacions S.L.	5.156	5.063
(viii) Rent Expenses Paid		
Comercial Vila Veterinaria De Lleida S.L	10.818	10.818
(ix) Other Income		
Fendigo SA	46.969	7.688
Bremer Pharma Gmbh	69.288	2.370
Alivira Animal Health Limited, Ireland	132.343	49.658
Phytotherapeutic Solutions S.L.	6.023	1.781
Fendigo BV	504	6.291
Comercial Vila Veterinaria De Lleida S.L	11.359	-
Laboratorios Karizoo S.A. De C.V.	4.662	-
N-Vet AB	21.490	-
Alivira Animal Health Limited, Italy	7.079	-
(x) Legal Professional Fees Paid		
Alivira Animal Health Limited, Ireland	129.125	41.897
Comercial Vila Veterinaria De Lleida S.L	-	5.045
Alivira Animal Health Limited, India	-	412
Provet Veterinerlik Urunleri Tic. Ltd. Sti	31.425	-
Evanvet Distribuidora De Produtos Veterinarios Ltda	9.921	-
Vila Viña Participacions S.L.	228.378	-
(xi) Management services Received		
Laboratorios Karizoo S.A. De C.V.	120.000	-
(xii) Service charge Paid (Exp)		
Phytotherapeutic Solutions S.L.	5.127	-
Vila Viña Participacions S.L.	64.819	-
(xiii) Service charge Paid (Rcvd)		
Vila Viña Participacions S.L.	10.499	-
(xiv) Dividend Paid		
Vila Viña Participacions S.L.	64.901	229.651
(xv) Dividend Recd		
Laboratorios Karizoo S.A. De C.V.	-	-
(xvi) Management fees Paid		
Vila Viña Participacions S.L.	228.378	-
(xvii) Salaries Paid		
Ramon Vila Viña	252.070	201.750
Teresa Vila Viña	103.288	102.447



LABORATORIOS KARIZOO, S.A.

Notes to the financial statements for the year ended 31 March, 2022


All amounts are in Euros

C. Balance as at balance sheet date:

Particulars	Year ended 31 Mar 2022	Year ended 31 Mar 2021
(i) Trade payables		
Phytotherapeutic Solutions S.L.	92.620	42.359
Comercial Vila Veterinaria De Lleida S.L.	1.091	1.459
Alivira Animal Health Limited, Ireland	9.353	171.453
(ii) Trade Receivables		
Phytotherapeutic Solutions S.L.	19.683	37.433
Comercial Vila Veterinaria De Lleida S.L.	135.940	328.381
Alivira Animal Health Limited, Italy	266.067	154.917
Bremer Pharma GmbH	27.694	2.579
Fendigo SA	77.492	110.239
N-Vet AB	5.213	-
Alivira Animal Health Limited, India	901	1.303
Alivira Animal Health Limited, Ireland	112.291	49.658
Vila Viña Participacions S.L.	6.763	
Laboratorios Karizoo S.A. De C.V.	40.301	
Provet Veterinerlik Urunleri Tic. Ltd. Sti	31.425	
Evanvet Distribuidora De Produtos Veterinarios Ltda	3.532	
(iii) Loans & Advances to related parties		
Laboratorios Karizoo S.A. De C.V. (Loan)	20.000	20.000
Laboratorios Karizoo S.A. De C.V. (Interest receivable on Loan)	751	1.000
Alivira Animal Health Limited, Ireland (Loan)	764.968	1.314.663
Alivira Animal Health Limited, Ireland (Interest receivable on Loan)	3.535	5.096
Phytotherapeutic Solutions S.L. (Loan payable)	740.000	-
Phytotherapeutic Solutions S.L.	1.426	-

As per our report of event date
BOVE MONTERO Y ASOCIADOS
 Auditors & Consultants
 Place : Barcelona, Spain
 Date :


FOR AND ON BEHALF OF THE BOARD OF DIRECTORS



KARIZOO

LABORATORIOS KARIZOO, S.A
 NIF: A08816502

Eusebi Vila Viña
 Director

Ramon Vila Viña
 Director